Back
Phreesia investors face class action over alleged securities losses

Phreesia investors face class action over alleged securities losses

The Schall Law Firm said investors who bought Phreesia securities from May 8, 2025, to March 30, 2026, may seek to join a securities class action before the July 13, 2026 deadline.

Fact Check
The Pomerantz and Holzer & Holzer press releases both directly confirm every element of the claim: a securities class action targeting investors who bought AVAV shares between June 25, 2025 and March 10, 2026, focused on statements about the Space Force SCAR antenna program (BADGER phased array antennas) and the contract's stop-work order (Jan 20, 2026), reopening/reassessment (Mar 2, 2026), and eventual termination disclosed March 10, 2026. Independent corroboration from SpaceNews (the cited source reporting the Space Force reassessing SCAR) and multiple other law firm notices (Robbins Geller, Levi & Korsinsky, Berger Montague) confirms the substance.
Summary

The Schall Law Firm announced a securities class action against Phreesia, Inc. on behalf of investors who purchased the company’s securities between May 8, 2025, and March 30, 2026. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, claiming Phreesia misled investors about the basis for its long-term growth outlook, its fiscal 2027 growth projections, and the expected contribution of pharmaceutical marketing commitments to growth in its Network Solutions segment. The firm said investors suffered damages when the market learned the truth and urged affected shareholders to contact it before July 13, 2026. It also said the class has not yet been certified, so investors are not represented by counsel unless they take action.

Terms & Concepts
  • class action lawsuit: A legal case brought by one or more plaintiffs on behalf of a broader group of investors with similar claims.
  • Rule 10b-5: An SEC anti-fraud rule that bars material misstatements, omissions, or deceptive conduct in connection with the purchase or sale of securities.
  • Network Solutions segment: A business unit referenced in the complaint as a source of expected growth tied to pharmaceutical marketing commitments.